HC Wainwright Reaffirms “Buy” Rating for Veru (NASDAQ:VERU)

HC Wainwright reissued their buy rating on shares of Veru (NASDAQ:VERU) in a research report report published on Friday,Benzinga reports. The firm currently has a $3.00 price target on the stock.

Separately, Oppenheimer reissued an “outperform” rating and issued a $5.00 target price on shares of Veru in a research note on Tuesday, November 5th.

Veru Price Performance

Shares of Veru stock opened at $0.65 on Friday. The stock has a market capitalization of $95.15 million, a P/E ratio of -1.35 and a beta of -0.50. Veru has a one year low of $0.36 and a one year high of $1.92. The business’s 50 day simple moving average is $0.74 and its two-hundred day simple moving average is $0.81.

Veru (NASDAQ:VERU) last posted its quarterly earnings results on Monday, December 16th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. Sell-side analysts expect that Veru will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Veru

Several institutional investors and hedge funds have recently modified their holdings of VERU. Perceptive Advisors LLC raised its stake in Veru by 26.5% in the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock worth $5,942,000 after buying an additional 1,478,578 shares in the last quarter. Choreo LLC raised its position in shares of Veru by 261.3% in the 2nd quarter. Choreo LLC now owns 332,050 shares of the company’s stock worth $292,000 after acquiring an additional 240,134 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Veru in the 2nd quarter valued at approximately $161,000. Bank of New York Mellon Corp boosted its position in shares of Veru by 1,718.2% during the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock valued at $373,000 after purchasing an additional 419,374 shares in the last quarter. Finally, PVG Asset Management Corp bought a new stake in shares of Veru during the second quarter valued at approximately $474,000. 47.16% of the stock is owned by hedge funds and other institutional investors.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.